Thrombotic thrombocytopenic purpura by Kremer Hovinga, Johanna A et al.
Thrombotic thrombocytopenic purpura (TTP; also 
known as Moschcowitz disease) is a life-threatening 
occlusive disorder of the microcirculation that is charac-
terized by systemic platelet clumping, organ ischaemia 
(especially of the brain, heart, gastrointestinal tract and 
kidneys), profound thrombocytopenia (a low blood plate-
let count, <100 × 109 cells per litre, often <30 × 109 cells per 
litre) and fragmentation of red blood cells. The disease 
was first described by Eli Moschcowitz in 1924 (REF. 1); 
however, its cause remained enigmatic until Moake et al.2 
reported four patients with chronic relapsing TTP who 
lacked the capacity to process von Willebrand factor 
(vWF). Subsequently, other investigators demonstrated 
that this inability to cleave vWF was the result of a severe 
deficiency of a metalloproteinase3–5, which was later 
characterized as a disintegrin and metalloproteinase 
with thrombospondin motifs 13 (ADAMTS13; FIG. 1) 
and identified as the protein with vWF-processing activ-
ity that was defective or lacking in TTP6–10. Thus, TTP 
is defined as thrombotic microangiopathy (TMA) with 
severe deficiency of ADAMTS13 activity.
Severe ADAMTS13 deficiency (<10% of the nor-
mal enzyme activity) is the result of either homozygous 
or compound heterozygous mutations in ADAMTS13 
(REFS 9,11–15) (hereditary or congenital TTP (cTTP); 
also known as Upshaw–Schulman syndrome16,17 
(Online  Mendelian Inheritance in Man (OMIM) 
#274150)), or of anti-ADAMTS13 autoantibodies in 
acquired, immune-mediated TTP (iTTP)3–5,18, which is 
the more prevalent form. TTP is a chronic condition that 
can manifest as acute episodes of TMA.
Although a rare disease, TTP is the focus of much 
investigation by clinicians and researchers because of its 
complex pathophysiology, the still high mortality of acute 
episodes (up to 20%) and the continuing risk of relapse 
in survivors of a first acute disease episode19. In this 
Primer, we discuss the molecular and clinical aspects of 
TTP, as well as future research directions. We also dis-
tinguish TTP from other TMAs that have similar clinical 
 presentations but often a distinct pathophysiology.
Epidemiology
iTTP
iTTP mainly affects adults, with peak incidences in the 
third to fifth decades of life in Europe and the United 
States20–23, and in the seventh decade of life in Japan24. 
Similarly to other autoimmune diseases, black (African 
Americans or African Caribbeans) individuals and 
women are more frequently affected than non-black 
individuals and men, with female to male ratios  ranging 
from 2.5:1 to 3.5:1 in different cohorts21,22. Of note, 
in the Japanese cohort, men and women ≥60 years of 
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Abstract | Thrombotic thrombocytopenic purpura (TTP; also known as Moschcowitz disease) is 
characterized by the concomitant occurrence of often severe thrombocytopenia, microangiopathic 
haemolytic anaemia and a variable degree of ischaemic organ damage, particularly affecting the brain, 
heart and kidneys. Acute TTP was almost universally fatal until the introduction of plasma therapy, which 
improved survival from <10% to 80–90%. However, patients who survive an acute episode are at high risk 
of relapse and of long-term morbidity. A timely diagnosis is vital but challenging, as TTP shares symptoms 
and clinical presentation with numerous conditions, including, for example, haemolytic uraemic 
syndrome and other thrombotic microangiopathies. The underlying pathophysiology is a severe 
deficiency of the activity of a disintegrin and metalloproteinase with thrombospondin motifs 13 
(ADAMTS13), the protease that cleaves von Willebrand factor (vWF) multimeric strings. Ultra-large vWF 
strings remain uncleaved after endothelial cell secretion and anchorage, bind to platelets and form 
microthrombi, leading to the clinical manifestations of TTP. Congenital TTP (Upshaw–Schulman 
syndrome) is the result of homozygous or compound heterozygous mutations in ADAMTS13, 
whereas acquired TTP is an autoimmune disorder caused by circulating anti‑ADAMTS13 autoantibodies, 
which inhibit the enzyme or increase its clearance. Consequently, immunosuppressive drugs, such as 
corticosteroids and often rituximab, supplement plasma exchange therapy in patients with acquired TTP.
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age were equally affected24. iTTP is very rare in individ-
uals <18 years of age, with considerable numbers only 
reported among Japanese24 and Polynesian popula-
tions25, who possibly share a common ethnic origin in 
South East Asia.
The annual incidence of clinically diagnosed, idio-
pathic TMA (irrespective of ADAMTS13 activity) was 
estimated at between 3.7 and 4.43 cases per million20,26 
and the incidence of iTTP was estimated to be 2.17 cases 
per million (95% CI: 2–2.34)22. Point prevalence estim-
ates of adult-onset iTTP and its proportion among all 
forms of TMA were reported for France (13 cases per 
million and 24%, respectively), and calculated for 
Oklahoma (18 cases per million and 23%) and Japan 
(3 cases per million and 21%)23.
Additional autoimmune manifestations or even dis-
orders are frequently observed in patients with iTTP19,24,27,28. 
In particular, patients with iTTP and also underlying 
connective tissue diseases, especially systemic lupus 
erythematosus, are considered a special entity and often 
show severe ADAMTS13 deficiency in the presence of 
non-inhibitory anti-ADAMTS13 autoantibodies29,30.
Besides ethnicity, evidence exists for a certain genetic 
predisposition to develop pathogenic anti-ADAMTS13 
autoantibodies. In white individuals, the HLA‑DRB1*11 
allele of the major histocompatibility complex (MHC) 
class II gene family was found to be over-represented in 
patients with iTTP, whereas HLA‑DRB1*04 was more 
prevalent among healthy controls, suggesting a protec-
tive effect of this allele31–33. The overall lower prevalence 
of HLA‑DRB1*04 in black individuals might contribute 
to their higher susceptibility to develop iTTP34. However, 
familial occurrence of iTTP has been reported in two 
families, even though none of the patients carried the 
HLA‑DRB1*11 allele35,36, pointing to other yet unidenti-
fied genetic risk factors. Finally, among patients diagnosed 
with acute iTTP, carriers of heterozygous ADAMTS13 
mutations have been observed37–39. Of seven patients 
with iTTP who carried heterozygous ADAMTS13 muta-
tions, six had anti-ADAMTS13 IgG autoantibodies that 
were functional inhibitors and one had non-inhibitory 
anti-ADAMTS13 autoantibodies. Given the overall low 
prevalence of ADAMTS13 mutations (see below), the 
number of heterozygous ADAMTS13 mutation  carriers 
among patients diagnosed with iTTP is remarkable 
and hints at a role of ADAMTS13 sequence variants in 
trigger ing the development of anti-ADAMTS13 auto-
antibodies or in expediting a drop in ADAMTS13 activ-
ity below a critical threshold to set off an acute iTTP 
episode. Of note, obligatory heterozygous ADAMTS13 
mutation carriers, such as parents of patients with cTTP, 
typically have an ADAMTS13 activity of about 50% and 
are generally healthy, although mild thrombocytopenia 
during pregnancy or infections has been reported in 
some of them40,41.
cTTP
In cTTP, severe ADAMTS13 deficiency is the result of 
compound heterozygous or homozygous mutations 
in ADAMTS13. More than 100 different causative 
ADAMTS13 mutations have been identified, including 
missense (~62%), nonsense (~12.5%), splice site (~8%) 
and frameshift (deletions or insertions; ~17.5%) muta-
tions, spreading over all ADAMTS13 protein- coding 
domains9,11–15,42–47. As is typical of autosomal recessive 
disorders, individuals carrying homozygous ADAMTS13 
mutations are primarily found in  families with docu-
mented parental consanguinity, with the exception of 
two recurring ADAMTS13 mutations: the frameshift 
mutation c.4143_4144dupA in exon 29 and the 
 missense mutation c.3178C>T (p.R1060W) in exon 24 
(REFS 12,38,42,46–48). Whereas c.4143_4144dupA has 
been described in families originating from central and 
northern Europe and accounted for many cases of cTTP 
among unrelated individuals in Scandinavia and around 
the Baltic Sea42,46, the distribution of p.R1060W is even 
more widespread. It is the predominant mutation in 
British and French patients, but has also been reported 
in families with a history of cTTP from Scandinavia, 
central Europe, Italy and Turkey, as well as in North 
Americans of European descent38,47.
cTTP affects men and women equally. Although the 
prevalence of cTTP is unknown, it has been postulated 
that it accounts for <5% of all acute cases of TTP23,49. 
A population screening in healthy Japanese adults, strati-
fied according to levels of ADAMTS13 activity, iden-
tified a substantial number of carriers of heterozygous 
ADAMTS13 mutations, and the authors speculated that 
the actual prevalence of cTTP could be up to threefold 
higher than the estimate based on diagnosed patients 
(~0.4 cases per million)50. The point prevalence of cTTP 
in central Norway was 16.7 cases per million46. This 
number was mirrored by an allelic frequency of the two 
most prevalent ADAMTS13 mutations in this popula-
tion, c.4143_4144dupA and c.3178 C>T (p.R1060W) 
of 0.04–0.33% and 0.3–1%, respectively. A slightly lower 
allelic frequency (0.06%) for the p.R1060W mutation was 
documented in the Rotterdam study, a population-based 
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cohort study in the Netherlands51. In all  population 
screen ings carried out to date, only  heterozygous 
 mutation  carriers have been identified.
Age at diagnosis in cTTP shows a bimodal distrib-
ution, with about half of patients presenting with their 
first episode of TTP by 2–5 years of age, and a second peak 
in early adulthood, with the inaugural episode specifically 
frequent during pregnancy41,43,52,53. Indeed, among women 
who had an episode of TTP during their first pregnancy, 
the frequency of cTTP was 25–66%44,45. In this subgroup 
of women with cTTP, the prevalence of p.R1060W is 
remarkable: in the UK and French cTTP cohorts, 17 out 
of 23 (74%) and 16 out of 21 (76%) patients, respectively, 
were either compound heterozygous or homozygous 
carriers of this mutation23,45. Of note, patients with cTTP 
heterozygous for p.R1060W have regularly measurable 
residual ADAMTS13 activity of 3–6% of the physio-
logical levels; homozygous p.R1060W carriers even have 
5–12%53,54. This observation suggests that, unlike most 
cTTP-associated mutations, which result in no residual 
ADAMTS13 activity, p.R1060W causes a less severe loss 
of enzymatic function. The level of residual ADAMTS13 
activity was suggested to be an important determinant 
of clinical severity with early onset (<18 years of age), 
the need for prophylactic plasma therapy and an annual 
event rate of >1 associated with ADAMTS13 activity of 
<3%53,55. However, the variable disease course in patients 
with a homozygous c.4143_4144dupA mutation (who 
typically have ADAMTS13 activity of <1%) suggests 
that there have to be additional determinants of clinical 
 severity in cTTP42,46.
Mechanisms/pathophysiology
ADAMTS13
ADAMTS13 is mainly synthesized in the liver by hepatic 
stellate cells8–10,56,57. In addition, renal podocytes and 
tubular epithelial cells48,58, platelets59 and endothelial 
cells60 synthesize biologically active ADAMTS13. After 
folding in the endoplasmic reticulum, ADAMTS13 
is active and is released as an active enzyme into 
the circulation61.
Apoptosis of hepatic stellate cells in rats or partial 
hepatectomy in rats and in humans led to a marked 
reduction in plasma ADAMTS13 activity to 30–40%62–64, 
which suggests that ADAMTS13 expression in other 
 tissues contributes to normal plasma levels of around 
1 μg per ml (REF. 6). The enzyme has a long plasma half-
life of 2–3 days65 and about 3–5% of ADAMTS13 circu-
lates bound to soluble vWF66. There is no physiological 
inhibitor of ADAMTS13 activity, and as of today, infor-
mation on pathways that are involved in ADAMTS13 
clearance is lacking.
Processing of vWF
The only known substrate for ADAMTS13 is vWF, 
a multimeric plasma glycoprotein that is exclusively 
synthesized by endothelial cells and megakaryocytes67 
(FIG. 2). vWF biosynthesis is complex and involves the 
removal of the signal peptide and propeptide, glyco-
sylation, sulfation, dimerization and, finally, multi-
merization68,69. Synthesized vWF multimers are either 
constitutively released from the endothelial cells or, 
more importantly, stored as ultra-large vWF multimers, 
Figure 1 | Structure of ADAMTS13. ADAMTS13 (which encodes a disintegrin and metalloproteinase with thrombospondin 
motifs 13, a metalloproteinase of 1,427 amino acids with a multidomain structure) is located on chromosome 9q34, covers 
about 37 kb (REF. 9) and neighbours the ABO blood group locus. The calculated molecular weight of ADAMTS13 is 145 kDa, 
and plasma‑purified ADAMTS13 has an apparent molecular weight of 180–190 kDa owing to glycosylation of about 20% of 
its mass. The schematic representation of the domain structure of ADAMTS13 shows: a signal peptide (SP), a propeptide (P), 
a metalloproteinase domain (M), a disintegrin‑like domain (D), a first thrombospondin type 1 repeat (T1), a cysteine‑rich 
domain (C), a spacer domain (S), seven thrombospondin type 1 repeats (T2–T8) and two CUB domains (CUB1 and CUB2) 
that are highly homologous to domains found in the complement receptor complex, complement C1r subcomponent–
complement C1s subcomponent (C1r–C1s), the embryonic sea urchin epidermal growth factor and bone morphogenetic 
protein 1. Almost all patients with acquired, immune‑mediated thrombotic thrombocytopenic purpura (iTTP) have anti‑ 
ADAMTS13 autoantibodies with an epitope in the spacer domain (antibody in green), although in many patients, 
anti-ADAMTS13 autoantibodies with epitopes in other ADAMTS13 domains are also present. In patients with hereditary 
TTP, mutations in ADAMTS13 (*) are spread over the different protease domains. Left inset: crystal structure of the DTCS 
domains with a modelled structure of the M domain. Five amino acid residues (shown in blue) — Arg568, Phe592, Arg660, 
Tyr661 and Tyr665 — constitute an antigenic surface that is recognized by the majority of the inhibitory anti‑ADAMTS13 
autoantibodies. The active site is indicated by a red arrow. Right inset: molecular model of ADAMTS13 as determined by 
small angle X-ray scattering. Left inset adapted with permission from REF. 223, National Academy of Sciences. Right inset 
reproduced with permission from REF. 74, National Academy of Sciences.
ADAMTS13
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together with an equimolar amount of vWF propeptide, 
in Weibel–Palade bodies (storage granules) in endothe-
lial cells or in α-granules of megakaryocytes and plate-
lets68,69. Upon stimulation by various agonists, such as 
cytokines (for example, tumour necrosis factor or IL-8) 
and histamine, or by fluid shear stress, ultra-large vWF 
multimers are rapidly secreted from endothelial cells 
and can remain anchored to the endothelial surface as 
long, string-like, hyper-adhesive structures or can be 
released into the circulation. The shear conditions of the 
blood flow unfold both anchored and freshly released 
ultra-large vWF multimers70,71, thereby exposing other-
wise cryptic platelet-binding sites and the ADAMTS13 
 cleavage site (FIG. 2b).
ADAMTS13 activity is regulated by conformational 
changes in its substrate, in a so-called molecular zipper 
mechanism72. Conformational activation was shown to 
also occur in ADAMTS13 (REFS 73–75), which circu-
lates in a closed conformation with its CUB domains 
interacting with the spacer domain73 (FIG. 1). Binding of 
vWF to this closed ADAMTS13 conformation leads to 
the exposure of functional exosites (secondary binding 
sites) in the ADAMTS13 spacer domain and, hence, con-
formational activation of the protease73,74. This process 
possibly optimizes vWF cleavage under fluid shear stress 
in vivo but might also make ADAMTS13 suscep tible 
to immune recognition73,74. Proteolysis of ultra-large 
vWF multimers generates shorter multi mers of vari able 
molecular weight, depending on where ADAMTS13 
cleavage takes place. The resulting smaller multimers 
again adopt a folded conformation, which prevents 
spontaneous binding of platelets and further digestion 
by ADAMTS13 (REF. 72).
TTP pathogenesis
When ADAMTS13 activity is lacking, ultra-large vWF 
multimers persist in the circulation (FIG. 3), and the spon-
taneous binding of platelets is no longer restrained. Thus, 
the ultra-large vWF multimers bind to, accumulate and 
activate platelets, forming the vWF-rich microthrombi 
that are a hallmark of TTP (FIG. 3b). These dissemin-
ated microthrombi scavenge platelets, which causes 
thrombo cytopenia, mechanically destroy red blood cells, 
which leads to haemolytic anaemia with fragmented red 
blood cells (schistocytes) that are visible on the periph-
eral blood smear, occlude the microcirculation and cause 
organ ischaemia.
Anti‑ADAMTS13 autoantibodies
iTTP is characterized by the appearance of inhibitory or 
non-inhibitory autoantibodies against ADAMTS13. In the 
majority of patients, strong functional ADAMTS13 
inhibitors can be demonstrated by Bethesda-like assays 
(see below)4,5,76. However, 10–25% of patients have 
non-inhibitory anti-ADAMTS13 autoantibodies, which 
have been postulated to acceler ate ADAMTS13 clear-
ance77–79. As the plasma levels of ADAMTS13 antigen 
are also severely reduced in the majority of patients with 
Figure 2 |  Structure of von Willebrand factor. a   |  Schematic 
representation of the domain structure of von Willebrand factor (vWF): 
a signal peptide (SP), five D domains (D1, D2, Dʹ, D3 and D4), three 
A domains (A1, A2 and A3), six C domains (C1–C6) and one cystine knot 
(CK) domain. The vWF A1 domain harbours the platelet glycoprotein Ib 
(GPIb) and a collagen‑binding site, the vWF A2 domain contains the a 
disintegrin and metalloproteinase with thrombospondin motifs 13 
(ADAMTS13) cleavage site, the vWF A3 domain has another collagen- 
binding site and the vWF C4 domain contains the platelet integrin 
αIIbβ3-binding site69,224. The CK domain is involved in tail-to-tail 
dimerization and the DʹD3 domain in head-to-head multimerization of 
vWF dimers. Drawings represent the conformation of two propeptides 
and a vWF dimer. b | Domain structure of vWF with highlighted crystal 
structure of the folded A2 domain with hidden ADAMTS13 cleavage site 
(upper panel) and a model of the unfolded A2 domain with an accessible 
ADAMTS13 cleavage site, which occurs after shear-induced unfolding of 
vWF (lower panel). First, ADAMTS13 binds through its thrombospondin 
type 1 repeats T5‑CUB domains to the D4‑CK domains of folded vWF66,225. 
Next, shear forces expose cryptic vWF A2 domain exosites, which interact 
with the ADAMTS13 spacer domain72, followed by the ADAMTS13 
disintegrin-like domain and the metalloproteinase domain, which finally 
proteolyses the Tyr1605–Met1606 scissile bond in the vWF A2 domain226. 
Part b adapted with permission from REF. 223, National Academy 
of Sciences.
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iTTP, clearance of the enzyme is probably an important 
contributing mechanism to the reduced protease  activity, 
besides the direct  inhibition by autoantibodies78–80.
Autoantibodies that recognize the spacer domain of 
ADAMTS13 are present in 97–100% of patients with 
iTTP79,81–83, and virtually all inhibitory anti-ADAMTS13 
autoantibodies that are identified by routine assays are 
directed to the ADAMTS13 spacer domain79. Epitope 
fine mapping showed that five amino acid residues 
(FIG. 1) constituted the principal antigenic surface for 
the majority of inhibitory anti-ADAMTS13 autoanti-
bodies84–88. However, the autoimmune response against 
ADAMTS13 is polyclonal, and about two-thirds of 
patients also have antibodies against other ADAMTS13 
domains79,81–83, although these epitopes have not been 
fine mapped.
Non-inhibitory anti-ADAMTS13 autoantibodies 
have also been observed in 4–15% of healthy controls 
and blood donors, as well as in numerous patients with 
cTTP, in whom titres were often fluctuating. In some 
of these patients with cTTP, the treatment interval of 
regular plasma prophylaxis to supplement ADAMTS13 
levels had to be shortened based on clinical judgement 
(mainly because of the development of neurocognitive 
symptoms), despite full recovery and a normal plasma 
half-life of infused exogenous plasma ADAMTS13 
(REFS 40,43). So far, functional ADAMTS13 inhibitors 
have been described in only two patients with cTTP43,89. 
These inhibitors were not boosted by subsequent plasma 
therapy, and are thus reminiscent of low-titre inhibitors 
in haemophilia A.
Anti-ADAMTS13 autoantibodies are predomin-
antly of the IgG class, but also IgM and IgA have been 
reported in a limited number of patients with iTTP29,90,91. 
Among the anti-ADAMTS13 IgG autoantibodies, the 
IgG4 subclass prevails, followed by IgG1, IgG2 and IgG3 
(REFS 86,91). High IgG4 titres were shown to be associ-
ated with an increased risk of relapse, and IgG4 was often 
the only anti-ADAMTS13 isotype. In a small number of 
patients, the presence of IgA or IgG1, or both, at pres-
entation with an acute TTP episode was associated with 
adverse outcome90,91.
Anti-ADAMTS13 autoantibodies frequently use 
VH1‑69 and VH1‑3 in the variable segment of the 
heavy-chain locus88,92, and somatic mutation rates of 
characterized anti-ADAMTS13 autoantibodies suggest 
affinity maturation88,92,93. In longitudinal studies over 
multiple relapses, functional maturation (that is, from 
non-inhibitory to inhibitory anti-ADAMTS13 auto-
antibodies) or epitope spreading (the development of an 
immune response to additional ADAMTS13 epitopes), 
or both, was demonstrated in some patients, suggesting 
a continuous shaping of the autoimmune response to 
ADAMTS13 in iTTP79,94.
The unexpectedly high ADAMTS13 antigen plasma 
levels in some samples of patients with iTTP, despite the 
presence of anti-ADAMTS13 autoantibodies, prompted 
the detection of circulating ADAMTS13 immune com-
plexes78, which are formed by the integral binding of 
ADAMTS13 to an anti-ADAMTS13 autoantibody. 
These enzymatically inactive immune complexes 
were subsequently found not only during acute epi-
sodes and relapses94–97 but also in patients in clinical 
 remission, even years after the last acute TTP episode96. 
Moreover, the presence of ADAMTS13 immune com-
plexes seemed to be predictive of a higher probability of 
recurrence of acute TTP events in the first 2 years after 
disease onset97.
The mechanisms involved in the loss of tolerance 
to ADAMTS13 remain unknown. The formation and 
maturation of antibodies requires immune recognition, 
endocytosis and processing of ADAMTS13 into peptides 
that are presented on MHC class II molecules of antigen- 
presenting cells. Sugar moieties on ADAMTS13 can 
interact with mannose receptors on antigen- presenting 
cells, thereby promoting endocytosis of the protease98. 
Studies have shown that peptides derived from the 
CUB2 domain of ADAMTS13 were presented by MHC 
class  II molecules encoded by HLA‑DRB1*11 and 
HLA‑DRB1*03 and that patients with iTTP had circu-
lating CD4+ T cells in peripheral blood that were reactive 
to peptides derived from the CUB2 domain99,100.
Diagnosis, screening and prevention
Clinical presentation
TTP often presents with an acute onset and severe dis-
ease course101. Amorosi and Ultmann102 reviewed 271 
patients from the literature and delineated the diag-
nostic pentad of clinical findings that were present in 
88–98% of patients (however, owing to early diagnosis, 
the complete pentad is now rarely present in patients 
diagnosed with acute TTP101,103–106). These signs are fever, 
purpura or haemorrhage associated with thrombo-
cytopenia, haemolytic anaemia with schistocytes on 
the blood smear, neurological manifestations (which 
are often transient, ranging from headache or mental 
changes to focal signs, seizures and coma) and vari-
able degrees of renal dysfunction. Haemolytic uraemic 
syndrome (HUS), which is a TMA that predominantly 
affects the kidneys, was recognized as one of the possible 
 differential diagnoses107.
Although the onset of disease is typically sudden, 
prodromal manifestations (including fatigue, arthralgia, 
myalgia and abdominal or lumbar pain) that suggest a 
flu-like episode are frequently reported at the time of 
diagnosis or during the preceding days. Cardiac events 
may include non-ST-elevation myocardial infarction 
(non-STEMI) and STEMI, congestive heart failure, 
arrhythmias, cardiogenic shock and sudden cardiac 
arrest. An increased serum cardiac troponin level 
upon presentation was an accurate predictor of subse-
quent acute myocardial infarction, as well as death and 
treatment refractoriness108,109. Digestive tract involve-
ment, including abdominal pain, nausea, vomiting and 
diarrhoea, was reported in up to one-fourth of cases. 
Autopsy studies revealed that microvascular thrombi 
are present in almost all organs: particularly in the brain 
(primarily in the cerebral cortex), heart, kidneys and the 
digestive tract, but also in the spleen, pancreas and 
 adrenal glands. In the absence of adequate management, 
patients develop multiple organ failure and eventually 
die within days or weeks.
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Differential diagnosis of TTP
The clinical signs, even when all symptoms of the clas-
sic pentad are simultaneously present, are not specific 
for TTP, and a series of other TMAs and disorders that 
result in similar manifestations have to be considered. 
Because TTP is a medical emergency, a rapid diagnosis 
is essential. Assessment of ADAMTS13 activity is piv-
otal in evaluating a patient who presents with an acute 
TMA. However, the results of ADAMTS13 activity 
assays are not always readily available, and because of 
high mortality rates, treatment cannot be postponed. 
Thus, a presumptive diagnosis has to be made and 
treatment initiated based on clinical presentation, the 
presence or absence of certain conditions or comorbid-
ities and routine laboratory tests (FIG. 4). Although the 
leading signs might guide the clinician in formulating 
Figure 3 | Pathophysiology of TTP. a | A microvessel (arteriole or capillary) in a healthy individual. Proteolysis by a 
disintegrin and metalloproteinase with thrombospondin motifs 13 (ADAMTS13) of ultra‑large von Willebrand factor 
(vWF) multimeric strings that are anchored to or secreted from stimulated microvascular endothelial cells. ADAMTS13 
cleaves the A2 domain of a vWF monomeric subunit at Tyr1605–Met1606 to prevent and regulate platelet adherence 
(via glycoprotein Ib) to the A1 domain. b | A microvessel in thrombotic thrombocytopenic purpura (TTP). When ADAMTS13 
activity is <10% of normal level, cleavage of secreted or anchored ultra-large vWF strings is severely reduced. The results 
are: excessive microthrombi formation, shear injury to red blood cells flowing through microvessels that are partially 
occluded by platelet clumps (producing schistocytes and haemolysis) and activation of the alternative complement 
pathway on the uncleaved ultra‑large vWF strings (inset). Activated complement factors C3 (C3b) and B (Bb) attach to a 
string in complexes of C3b–Bb (C3 convertase) and C3b–Bb–C3b (C5 convertase). C3a and C5a are anaphylatoxins that 
are liberated by proteolytic cleavage of C3 and C5, respectively. Other components that bind to uncleaved ultra‑large 
vWF strings are: complement factor D (not shown), which cleaves and activates factor B; complement factor P (properdin), 
which stabilizes C3 convertase and C5 convertase; and complement factor H and factor I (not shown), which are the 
negative regulators of C3 convertase. However, the binding of factor H and factor I is insufficient to block C3 convertase 
activity generated on the strings. c | Plasma vWF. Sodium dodecyl sulfate (SDS)–agarose gel electrophoresis of plasma 
from a healthy individual (control) and a patient with congenital TTP (cTTP) in remission highlights high-molecular-weight 
(HMW) vWF multimers and ultra‑large (UL) vWF multimers. Of note, ultra‑large vWF multimers are less likely to be seen 
during relapse, perhaps because these hyperadhesive forms adhere to and aggregate platelets in the microcirculation. 
MAC, membrane attack complex.
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a diagnosis, it should be kept in mind that none of 
the routine biomarkers, such as creatinine and lactate 
dehydro genase levels and platelet counts, is specific for 
or can formally rule out one condition.
Shiga toxin-associated HUS. A differential diagno-
sis of TTP is Shiga toxin (STX)-associated HUS (also 
known as typical HUS), caused by STX-producing, 
enterohaemorrhagic bacteria, mainly Escherichia coli. 
STX-HUS mostly occurs in children <5 years of age 
and is rarely seen in adults110. Following a prodromal 
phase of diarrhoea, which turns bloody after 1–2 days, 
patients present 5–7 days later with a clinical triad 
of thrombocytopenia, microangiopathic haemolytic 
anaemia and often severe renal insufficiency. These 
patients have generally normal or only mildly reduced 
ADAMTS13 activity111,112. However, surprisingly, 1 out 
of 29  children with STX-HUS in a study by Hunt et al.111 
had an acquired severe ADAMTS13 deficiency that had 
resolved when tested 3 years later. Furthermore, 21 
of 322 adult patients from the Oklahoma TTP-HUS 
registry presented with bloody diarrhoea, and E. coli 
O157:H7 was identified in some of them, although 
not all patients were systematically tested113. Two of 
16 patients of this study who were tested had a severe 
ADAMTS13 deficiency113. Finally, during the German 
E.  coli O104:H4 outbreak in 2011, two out of six 
severely affected patients investigated showed a severe 
autoantibody- mediated ADAMTS13 deficiency114, sug-
gesting a final diagnosis of iTTP, possibly triggered by 
enterohaemorrhagic E. coli infection. Altogether these 
observations suggest that severe enterohaemorrhagic 
E. coli infection might lead not only to STX-HUS but, 
in rare cases, also to an autoimmune response against 
ADAMTS13, or that STX could trigger acute TMA 
in a few patients with a pre-existing autoimmune 
response against ADAMTS13. Of note, STX can bind 
to a restricted region between the vWF A1 and A2 
domains, thereby reducing the rate of vWF proteolysis 
by ADAMTS13 (REF. 115).
Atypical HUS. Another differential diagnosis of TTP 
that must be considered, especially when renal insuffi-
ciency is prominent, is atypical HUS (aHUS), which 
is often linked to uncontrolled activation of the alter-
native pathway of the complement system. Various 
mechanisms can underlie this excessive activation: 
gain-of-function mutations in C3 and CFB (the genes 
encoding the complement factor C3 and complement 
factor B, respectively); defective complement regula-
tion due to mutations in CFH, CFI, CD46 (also known 
as MCP) or THBD, which encode complement factor H 
(CFH), complement factor I (CFI), membrane  cofactor 
protein (MCP) and thrombomodulin, respectively; 
or autoantibodies against CFH. CFH mutations are the 
most prevalent, accounting for ~25% of identified muta-
tions in individuals with aHUS, followed by mutations 
in CD46 and CFI116,117. aHUS is rare: it is estimated to 
account for <5% of all HUS cases, and penetrance varies 
depending on the underlying mutation. Besides familial 
occurrence, sporadic cases have been reported116,117.
Drug-associated TMA. Several drugs, such as calcineu-
rin inhibitors, antineoplastic agents (that is, mitomycin C 
or gemcitabine), inhibitors of vascular endothelial 
growth factor, quinine or intravenous abuse of oral 
oxymorphone, have been implicated in the induction 
of acute TMA, usually with no associated ADAMTS13 
deficiency. An exception is ticlopidine, an antiplatelet 
drug of the thienopyridine family, which has rather fre-
quently led to acute TTP after 2–4 weeks of intake; in all 
instances investigated, a severe autoantibody- induced 
ADAMTS13 deficiency was found118,119. The newer 
thienopyridines, clopidogrel and prasugrel, which 
have replaced ticlopidine for safety reasons, rarely 
induce TMA. ADAMTS13 activity was usually normal 
and anti-ADAMTS13 inhibitory auto antibodies were 
usually absent in individuals who developed TMA as a 
consequence of clopidogrel treatment120,121.
TMA associated with haematopoietic stem cell trans-
plantation or disseminated neoplasia. TMA associ-
ated with haematopoietic stem cell transplantation is 
almost never accompanied by severe ADAMTS13 defi-
ciency19,122–124. However, endothelial cell toxicity caused 
by either preceding chemotherapy or irradiation, or a 
graft-versus-host reaction to host endothelial cells125 
might have a pathophysiological role. Similarly, TMA 
associated with disseminated neoplasia, often present-
ing with a pronounced leukoerythroblastic haemogram 
that is indicative of bone marrow metastasis, is seldom 
accompanied by severe ADAMTS13 deficiency19,122–124.
HIV infection. The percentage of patients with acute 
TMA who also have HIV infection varies consider ably 
in different case series, from 0 out of 48 patients (0%) 
to 20 out of 24 patients (83%), and depends on the 
geographical location and hence the prevalence of HIV 
infection, as well as the availability of health care and 
highly active antiretroviral therapy126. In South Africa, 
HIV infection is by far the most common cause of 
TMA127, whereas in Europe, before antiretroviral ther-
apy became available, 1–2% of patients with HIV infec-
tion developed a TMA, which, after the intro duction of 
antiretroviral therapy, is now hardly seen128. In a pro-
spective registry from France, 29 out of 236 patients 
with acute TMA also had HIV infection129. Of these 
patients, 17 out of 29 had an ADAMTS13 activity of 
<5% and had fewer AIDS-related complications and 
higher CD4+ T cell counts than the 12 patients with an 
ADAMTS13 activity of >5%. The prognosis was better 
in those with severe autoimmune ADAMTS13 defi-
ciency129, who probably had iTTP secondary to HIV 
infection. The other 12 patients with an ADAMTS13 
activity of >5% had another form of TMA, which was 
possibly related to infectious complications. Of  special 
interest is one patient infected with HIV from the 
Oklahoma TTP-HUS registry who had recurring 
 classic TMA bouts with documented anti-ADAMTS13 
autoantibodies from the first presentation but 
severe ADAMTS13 deficiency only in later acute epi-
sodes94,126, indicative of antibody shaping or  maturation 
over time.
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Connective tissue disorders. TMA can occur in individ-
uals affected by connective tissue disorders, including 
systemic lupus erythematosus, rheumatoid arthritis 
and systemic sclerosis. A large study from Japan that 
included 127 patients with TMA associated with con-
nective tissue disorders showed that the majority of these 
patients had normal or mildly to moderately decreased 
ADAMTS13 activity, although some patients with sys-
temic lupus erythematosus or rheumatoid arthritis had 
a severe autoantibody-mediated ADAMTS13 deficiency 
and, therefore, iTTP secondary to connective tissue 
disorders30. Thus, iTTP secondary to systemic lupus 
 erythematosus is possible.
Pregnancy-induced TMA. Correctly diagnosing preg-
nant women who present with an acute TMA is challeng-
ing, as pregnancy has been associated with a wide range 
of TMAs44,105,130. Pre-eclampsia and HELLP (haemolysis, 
elevated liver enzymes and low platelets) syndrome show 
features that are difficult to distinguish from classic TTP. 
Arterial hypertension and oedema in pre-eclampsia and 
severe liver damage in HELLP syndrome are differential 
diagnostic clues. Both pre- eclampsia and HELLP syn-
drome usually manifest in the third trimester, typically 
after the 34th gestational week and promptly resolve 
within days after delivery103. In HELLP syndrome, 
ADAMTS13 activity is normal or mildly reduced, but 
the vWF A1 domain might be more often in a glyco-
protein Ib-binding conformation131. cTTP is much less 
common than HELLP, but might first manifest during 
pregnancy44,52,130,132. Virtually every woman with cTTP 
will have an acute episode of TTP during her first preg-
nancy, often before the third trimester, even if she had 
been asymptomatic until then. iTTP can also manifest 
during pregnancy44. However, whereas women with 
cTTP will almost invariably show a disease flare-up 
during an ensuing pregnancy, women with iTTP who 
experience an episode during their first pregnancy seem 
to have a moderate risk of relapse but an increased risk of 
pre-eclampsia in a consecutive pregnancy133.
ADAMTS13 assays and interpretation
The status of ADAMTS13 in a patient can be assessed in 
various ways. Activity assays measure the ability of the 
enzyme to cleave vWF multimers or vWF peptides, anti-
body assays determine the presence of anti-ADAMTS13 
autoantibodies and/or their inhibitory potential, and 
antigen assays measure the plasma concentration of 
the protease (TABLE 1). ADAMTS13 activity assays using 
multimeric vWF substrate used to be difficult to per-
form and laborious. In 2004, Kokame et al.134 found 
that the minimal functional substrate for ADAMTS13 
comprised 73 amino acid residues (D1596 to R1668) 
in the vWF A2 domain and developed a fluorescence 
resonance energy transfer (FRET)-based assay135. This 
FRETS-VWF73 assay and other similar assays136 have 
become widely available in diagnostic laboratories, show 
very good reproducibility and are now pushing towards 
detection limits below 5%135–139. The presence and levels 
of functional ADAMTS13 inhibitory autoantibodies are 
assessed in a Bethesda-like assay by mixing a sample of 
heat-inactivated plasma from the patient with a plasma 
pool from healthy controls and measuring the residual 
ADAMTS13 activity in the mixture. The inhibitory 
autoantibodies in the plasma of the patient neutralize 
ADAMTS13 that is present in the control sample. One 
inhibitor unit (Bethesda unit per ml) is defined as the 
amount of autoantibodies that reduces ADAMTS13 
activity in control plasma to 50%140. The total plasma 
level of anti-ADAMTS13 IgG antibodies (whether 
inhibitory or non-inhibitory) can be assessed by various 
custom- made or commercially available enzyme-linked 
immunosorbent assays (ELISAs), using ADAMTS13 as 
immobilized antigen. In addition, the plasma levels of 
ADAMTS13 antigen can be assessed by ELISA, but the 
levels of ADAMTS13 antigen are not considered relevant 
for diagnosis or for guiding treatment in TTP.
There are limitations to each of these tests. In the 
FRETS-VWF73 assay, free haemoglobin or bilirubin 
in the plasma of patients who are hyperbilirubinaemic, 
which may occur in TTP as a result of haemolysis, act 
as fluorescence quenchers, resulting in inaccurately low 
ADAMTS13 activity141. In the absence of protease inhib-
itors, such as Pefabloc SC (Sigma-Aldrich), other pro-
teases that are present in plasma samples might interfere 
with accurate measurement of ADAMTS13 activity136. 
Figure 4 | Diagnostic algorithm and likelihood of TTP. Diagnostic flowchart in a 
patient presenting with thrombotic microangiopathy (TMA), consisting of 
microangiopathic haemolytic anaemia and thrombocytopenia with or without organ 
failure. Monitoring a disintegrin and metalloproteinase with thrombospondin motifs 13 
(ADAMTS13) activity during remission contributes to distinguishing congenital 
thrombotic thrombocytopenic purpura (TTP) from immune-mediated TTP, as in the latter, 
ADAMTS13 activity should recover during remission. STX-HUS, Shiga toxin-producing, 
enterohaemorrhagic bacteria-induced haemolytic uraemic syndrome.
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In particular, leukocyte-derived proteases cleave near or 
at the scissile bond in the vWF A2 domain, which may 
theoretically lead to overestimating ADAMTS13 activ-
ity142. In patients with iTTP, extensive plasma dilution 
required for some assays might lead to the dissociation 
of ADAMTS13 immune complexes, resulting in over-
estimation of ADAMTS13 activity94. An improved assay 
using undiluted plasma samples has been reported143. 
ADAMTS13 inhibitor levels assessed by static assays are 
not always consistent with those obtained by assays per-
formed under flowing fluid conditions,  possibly because 
certain ADAMTS13 epitopes are selectively exposed 
under shear144 or because ADAMTS13 inhibitory 
autoantibodies that target an epitope in the ADAMTS13 
carboxy-terminal domains are not identified by vWF 
peptide-based activity assays. A negative result of a 
Bethesda-like assay or an antibody ELISA should be 
controlled in a second sample.
Distinction between iTTP and cTTP
Distinction between iTTP and cTTP is mandatory to 
help guide treatment and follow-up. In cTTP, the func-
tional ADAMTS13 inhibitory autoantibody test is neg-
ative, severely reduced ADAMTS13 activity persists 
over time and a full recovery of ADAMTS13 activity 
is expected upon plasma infusion with a plasma half-
life of infused ADAMTS13 of 2–3 days (REFS 65,145). 
Molecular analysis to determine the presence of caus-
ative ADAMTS13 mutations can help to distinguish 
between cTTP and iTTP.
Management
Acute TTP episodes are medical emergencies: max-
imal resuscitative measures might be required and the 
immedi ate outcome might not be predictable. In several 
centres, patients are routinely treated in intensive care 
units during the first few days. Older age, an increased 
plasma level of cardiac troponin, which indicates dam-
age to the myocardium, and very high levels of  lactate 
dehydro genase at diagnosis were associated with 
increased  mortality and treatment refractoriness108,109,146.
Plasma therapy
Plasma therapy is used to manage both iTTP and cTTP. 
There are two kinds of plasma therapy: plasma infu-
sions and therapeutic plasma exchange (TPE). TPE with 
replacement of fresh frozen or solvent detergent plasma 
remains the cornerstone of current management of iTTP. 
By replacing large volumes of the plasma of the patient, 
TPE replenishes the activity of ADAMTS13 and removes 
anti-ADAMTS13 autoantibodies, ADAMTS13 immune 
complexes, high-molecular-weight vWF multimers and 
inflammatory cytokines, although this removal has not 
been formally demonstrated. The introduction of TPE 
in the early 1980s led to an impressive improvement in 
the prognosis of TTP, with survival rates rising from 
<10% to >80%147. In 1991, a randomized controlled 
trial of plasma infusion versus TPE for the treatment of 
adult patients with TTP established a plasma volume- 
dependent response rate (defined as a platelet count of 
>150 × 109 cells per litre and no new neurological events) 
Table 1 | ADAMTS13 assays
Test Substrate Mechanism Output
ADAMTS13 activity
FRETS‑VWF73* vWF A2‑derived 
peptide
FRET using ADAMTS13 cleavable, fluorophore-tagged 
substrate
Fluorescence intensity is proportional 
to ADAMTS13 activity
vWF multimer 
assay*
Full-length vWF vWF proteolysis by ADAMTS13 in the presence of low-ionic 
strength and urea, and analysis of the vWF multimer size 
in SDS–agarose gels and western blotting
Reduction of vWF multimeric size is 
proportional to ADAMTS13 activity
vWF fragment 
assay*
Full-length vWF vWF proteolysis by ADAMTS13 in the presence of low-ionic 
strength and guanidinium chloride and SDS–polyacrylamide 
gel electrophoresis of cleaved vWF
Occurrence of disulfide‑linked dimers 
of carboxy‑terminal 176 kDa fragments 
is proportional to ADAMTS13 activity
Residual collagen- 
binding assay*
Full-length vWF Proteolysis of vWF by ADAMTS13 reduces the ability of vWF 
to bind to collagen
Reduction of vWF function is 
proportional to ADAMTS13 activity
Residual ristocetin 
cofactor assay*
Full-length vWF Proteolysis of vWF by ADAMTS13 reduces vWF ristocetin 
cofactor function
Reduction of vWF function is 
proportional to ADAMTS13 activity
Platelet string 
assay‡
Full-length vWF Endothelial cell cultures are stimulated to release long vWF 
strings, which are perfused with labelled platelets and plasma
Abundance of platelet strings is 
reciprocal to ADAMTS13 activity
Vortex assay‡ Full-length vWF vWF proteolysis by ADAMTS13 in the presence of shear 
stress, and analysis of vWF multimer size in SDS–agarose gels 
and western blotting
Reduction of vWF multimeric size is 
proportional to ADAMTS13 activity
Anti‑ADAMTS13 autoantibodies
Bethesda‑like 
assays*
Control plasma mixed 
with heat-inactivated 
patient plasma
Inhibitory anti-ADAMTS13 autoantibodies reduce 
ADAMTS13 activity of control plasma
Residual ADAMTS13 activity inversely 
correlates with the presence of 
functional inhibitory autoantibodies
ELISA* Immobilized 
ADAMTS13
Binding of anti‑ADAMTS13 autoantibodies in a plasma 
sample to immobilized ADAMTS13
Quantification of anti-ADAMTS13 
autoantibodies
ADAMTS13, a disintegrin and metalloproteinase with thrombospondin motifs 13; ELISA, enzyme-linked immunosorbent assay; FRET, fluorescence resonance 
energy transfer; SDS, sodium dodecyl sulfate; vWF, von Willebrand factor. *Static. ‡Flow.
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by day 9 of 47% for TPE versus 27% for plasma infusion, 
and survival at 6 months of 78% versus 49%, respec-
tively)148. TPE is performed daily until the platelet count 
has  stably recovered, haemolysis has ceased and no addi-
tional organ dysfunction occurs. TPE initially usually 
requires the exchange of 1.5 times the patient’s plasma 
volume, then the volume can be reduced to 1 times the 
patient’s plasma volume after a few days. A twice-daily 
TPE treatment in severe, initially refractory iTTP has 
been reported149,150, but the benefit of this regimen was 
difficult to assess as other treatments were often initiated 
or intensified simultaneously.
In cTTP, plasma infusions are usually sufficient, 
although, sometimes, a few TPE sessions might be 
required to treat acute episodes43–45,132. Regular plasma 
infusions are effective in preventing acute episodes in 
cTTP, but there are no official guidelines indicating when 
a prophylactic plasma regimen should be started.
Corticosteroids
Given the autoimmune nature of iTTP, there is a ration-
ale for the use of corticosteroids, although there are few 
randomized controlled trials. Before the systematic use 
of TPE was introduced, it was reported that 30 out of 
54 (55%) patients with TTP without consider able organ 
involvement responded within 48–72 hours to cortico-
steroids alone151. A randomized controlled trial compared 
standard-dose with high-dose methylprednisolone as an 
adjunctive therapy to TPE in 60 patients with newly diag-
nosed iTTP152. After 23 days of treatment, remission was 
achieved in 77% and 47% of patients in the high-dose and 
standard-dose arms, respectively. Following the introduc-
tion of corticosteroids as routine adjunctive treatment to 
TPE in the Oklahoma TTP-HUS registry, the reported 
number of TPE sessions required to achieve remission 
was reduced, a finding that was paralleled by a reduc-
tion of treatment-associated complications153. Altogether, 
these data indicate that corticosteroids in association 
with TPE are beneficial in the management of iTTP.
Biologic therapy
Rituximab, a humanized anti-CD20 monoclonal anti-
body that was originally developed to treat CD20+ B cell 
neoplasia, was first introduced as iTTP treatment in 
patients who had a suboptimal response (that is, dis-
ease exacerbation, defined as a recurrence of thrombo-
cytopenia during the period of daily TPE or within 
30 days of stopping TPE, or refractoriness) to con-
ventional therapy, with the aim of suppressing the 
production of anti-ADAMTS13 autoantibodies154–160. 
In these patients, daily TPE was usually continued 
and rituximab was administered periodically after a 
TPE session, most often weekly for 4 weeks (TABLE 2). 
Rituximab was associated with a rapid and substantial 
depletion of peripheral B cells, more-frequent recovery 
of ADAMTS13 activity and more-effective depletion of 
anti-ADAMTS13 autoantibodies. In addition, two 
prospective studies reported on patients treated with 
rituximab as front-line therapy158,161, which resulted 
in fewer and delayed relapses158–160, prompting the 
 suggestion that all patients with iTTP should be treated 
up-front with rituximab in conjunction with TPE; how-
ever, this suggestion is still being debated162. To pre-
vent overtreatment, it is important to consider that at 
least 50% of patients can recover from an acute iTTP 
episode with standard TPE alone or with the addition 
of corticosteroids4,19,124,148,163.
Splenectomy
Splenectomy was performed as a last resort in patients 
with TTP for many years with mixed results (reviewed 
in REF. 164) before the introduction of TPE and in the 
absence of any effective treatment. The understanding 
of the pathophysiology of iTTP now provides a ration-
ale to treat patients who relapse or are refractory to 
TPE and/or rituximab treatment by splenectomy76,88,165. 
A study reporting the long-term (median: ~9 years) 
follow-up of 33 patients with recurring or refractory 
TTP who underwent splenectomy showed that it led 
Table 2 | Reports involving ≥10 patients with acquired, immune-mediated TTP treated with rituximab in the acute phase
Refs n Complete 
remission 
achieved 
(%)
Median days 
to complete 
remission 
(range)
History of 
previous 
iTTP (%)
Relapse 
(%)
Median 
months 
to relapse 
(range)
Serious adverse events
Scully et al.154* 25 100 11 (7–21) 44 0 NA One fatal pneumonia, after achieving complete 
remission, and one morbilliform rash
Jasti et al.155‡ 12 83 18 (14–41) 8 8 23 One varicella zoster virus transverse myelitis 
and encephalitis
Ling et al.156‡ 13 92 NA 54 0 NA None
de la Rubia et al.157‡ 24 87.5 14 (7–35) 42 12.5 29 (7–29) None
Scully et al.158§ 40 82.5 12 (NA) 15 10 27 (17–31) None
Froissart et al.159* 22 82 12 ± 6.7 14 14 24 (20–36) None
Page et al. 160‡,|| 16 100 NA 0 12.5 30 and 118.8|| Formally none; however, two patients died of 
systemic lupus erythematosus during the study
Vazquez‑Mellado 
et al.161*,§,¶
11 100 NA 9 9 8 None
iTTP, acquired immune‑mediated thrombotic thrombocytopenic purpura; NA, data not available. *Prospective. ‡Retrospective. §Rituximab as front-line therapy. 
||Only survivors are reported (two additional patients died). ¶Rituximab dosage was lower than in all other studies.
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to remission in all but one patient, and the 10-year 
relapse-free survival in the whole cohort was 70%166. 
Comparing the efficacy of splenectomy with that of 
rituximab in the treatment of refractory or recurrent 
iTTP would require a difficult-to-perform randomized 
controlled trial. Evidence suggests that splenic B cells 
that produce anti-ADAMTS13 autoantibodies might 
escape anti-CD20 therapy in some patients88. If splenec-
tomy is considered in a patient with relapsing or refrac-
tory iTTP, a laparoscopic surgical procedure should be 
preferred, and the patient should at least be partially 
stabilized by TPE166.
Other drugs
Immunomodulatory drugs. These drugs aim to 
suppress the production of anti-ADAMTS13 auto-
antibodies in patients with refractory iTTP who had 
suboptimal responses to other treatments and are 
often prescribed as a last resort. Vincristine was used 
mainly in the pre-rituximab era. Although a review 
of 56 studies showed that 73% of patients receiving 
 vincristine achieved stable remission167, it is likely that 
many (or most) treatment failures of vincristine were 
not reported, as the confidence of haematologists in this 
drug to treat iTTP waned over the years and it is now 
rarely used.
Cyclosporine A has been reported to be effective168, 
with clinical responses correlating with improved 
ADAMTS13 activity and the suppression of anti- 
ADAMTS13 autoantibody production169. However, 
a recent randomized clinical trial showed no statistically 
significant difference in the exacerbation rate between 
patients treated with cyclosporine A or corticosteroids 
as adjunctive therapy170.
Platelet count and ADAMTS13 activity can recover 
with cyclophosphamide171, but because of its severe 
adverse effects (that is, bone marrow suppression, 
infectious complications, decreased fertility and a long-
term risk of malignancy), this drug is justified only in 
 rituximab-resistant, refractory patients.
Bortezomib, a proteasome inhibitor used to treat 
multiple myeloma and antibody-mediated rejection of 
transplanted solid organs, was effectively used to elimin-
ate anti-ADAMTS13 autoantibody-producing plasma 
cells that are resistant to the usual  immunosuppressive 
therapies in some patients172–175.
N-acetylcysteine. N-acetylcysteine (NAC) is approved 
for the treatment of acetaminophen toxicity or for 
bronchoalveolar obstruction, and has been shown to 
inhibit platelet adherence to endothelial cell-anchored 
vWF multimers (possibly soluble ones too)176,177 and 
to reduce the size of soluble high-molecular-weight 
vWF multimers in vitro176. The anti-thrombotic effect 
of NAC might predominantly result from the reduc-
tion of the 1278–1458 disulfide bond in the vWF A1 
domain that is important for vWF binding to platelet 
glycoprotein Ibα176–178.
Recent studies in animal models of TTP demon-
strated that NAC alone was effective in preventing 
the development of severe acute TTP signs (in mice), 
but could not reverse them once established (in mice 
and baboons)179. NAC has not been approved for use 
in TTP or other TMAs. As of 2017, three papers have 
described the successful ‘off-label’ use of NAC (in con-
junction with continued TPE) in five patients with 
refractory TTP178,180,181, whereas NAC treatment failed 
in three other patients with refractory TMA174,182–184.
Quality of life
Relapse
Each acute TTP episode exposes the patient to a risk 
of morbidity and mortality. The prevention of relapses 
is, therefore, a rationale to treat patients with TTP in 
clinical remission. In cTTP, relapses may become fre-
quent after the first episode and some patients depend 
on regular plasma infusions every 2–3 weeks to main-
tain normal platelet count and to avoid clinical TTP 
 manifestations and long-term morbidity52.
In iTTP, relapses occur in as many as 40% of patients 
who survive the first disease episode within 7–10 years 
of follow-up19. In a series of patients with other 
forms of TMA besides iTTP, relapses affected almost 
exclusively individuals with iTTP19,163, and recurrent 
episodes were usually associated with severe acquired 
ADAMTS13 deficiency90. Although a few patients with 
iTTP might achieve and remain in remission despite 
persisting severely reduced ADAMTS13 activity19,90,185, 
the majority of patients recover ADAMTS13 activity 
upon remission. It has been suggested that the decrease 
in ADAMTS13 activity during remission is a strong risk 
factor for ensuing disease recurrence186,187. Thus, routine 
measurements of ADAMTS13 activity and auto antibody 
titres may help in long-term disease management. In a 
small prospective study, lower ADAMTS13 activ-
ity and younger age were predictive of relapse within 
3 months, whereas inhibitory auto antibody titres were 
not correlated186. However, another study suggested that 
high titres of inhib itory anti- ADAMTS13 IgG antibod-
ies at presentation were associ ated with undetectable 
ADAMTS13 activity during remission and predicted 
relapses within 18 months90. Recently, Page et al.188 
reported on patients with iTTP from the Oklahoma 
TTP-HUS registry who had prolonged periods of 
severe ADAMTS13 deficiency without experiencing 
acute TTP episodes. In some patients, ADAMTS13 
activity recovered spontaneously to  normal levels and 
none of these patients relapsed, whereas up to 60% of 
patients with a severe ADAMTS13 deficiency in remis-
sion experienced at least one TTP relapse. The French 
TMA Reference Center Network recently reported 
their results on 30 patients with iTTP who were pre- 
emptively treated with rituximab during remission189. 
Rituximab reduced the incidence of relapse with min-
imal adverse effects; however, in about one-third of 
patients, further cycles of rituximab were required to 
maintain detectable levels of ADAMTS13 activity, and 
16% of patients required other immunomodulatory 
drugs and/or splenectomy189. Nevertheless, pre-emptive 
rituximab treatment should be considered for patients 
in remission who experience frequent and/or severe 
episodes of iTTP189.
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Comorbidities and sequelae
Many patients with iTTP experience reduced health- 
related quality of life190. Detailed neurocognitive investi-
gation of 24 patients who were followed up for a median 
of 4 years after an acute episode of iTTP revealed that 
their concentration, information processing, rapid 
language generation and memory performance were 
significantly worse than standardized adjusted data191. 
These deficits were interpreted as the result of diffuse 
subcortical microvascular disease, although they did not 
correlate with the presence or severity of neurological 
symptoms during the acute TTP episode or episodes.
Survivors (n = 57) of a first acute episode of iTTP 
who were enrolled in the Oklahoma TTP-HUS registry 
were followed up for a median of 8 years28. The point 
prevalences of arterial hypertension (40%) and major 
depression (19%) in these patients were greater than 
expected from the matched general population (23% 
and 6%, respectively). Furthermore, the mortality of 
the cohort was substantially higher than that of the 
US and local Oklahoma populations, respectively, and 
this increase was suggested to be related to the higher 
 number of comorbidities in patients with iTTP than in 
the general population28.
However, whether cognitive alterations, depression, 
arterial hypertension, other comorbidities and increased 
mortality are specific features of individuals who sur-
vive an acute episode of iTTP or are equally present in 
patients surviving other acute severe diseases remains 
to be investigated. In addition, a possibly ongoing auto-
immune response, evidenced by the presence of circu-
lating ADAMTS13 immune complexes even years after 
an acute iTTP episode96, as well as other autoimmune 
disorders (particularly connective tissue diseases) that 
might develop over time28,192 could have a role. The 
 creation of comprehensive prospective registries, regu-
lar follow-up and long-term observation will be instru-
mental in finally improving the outlook for patients with 
iTTP and cTTP.
Outlook
Although the clinicians’ awareness of TTP as well as our 
understanding of its underlying pathophysiology have 
substantially increased, diagnosing and treating TTP 
remain a challenge.
New drugs
vWF A1 domain targeted therapy. Two small molecules 
that specifically block the vWF A1 domain, thereby 
preventing platelet binding, have been tested in patients 
with iTTP. ARC1779, an oligonucleotide aptamer, was 
not further explored after early termination of the 
phase II trial owing to difficulties in patient recruit-
ment and financing, but the study still provided valu-
able proof of principle for the vWF A1 domain-blocking 
approach193,194. The second compound, caplacizumab 
(formerly known as ALX-0081), is a nanobody (that is, 
a single-domain antibody) derived from single-chain 
antibodies that naturally occur in Camelidae. It was 
assessed in the TITAN trial, a multicentre, randomized, 
placebo-controlled phase II study in patients with iTTP. 
Time to platelet recovery was significantly shorter and 
biomarkers reflecting ischaemic organ damage normal-
ized more rapidly in patients who received caplacizumab 
in addition to standard-of-care treatment195. The inci-
dence of exacerbations was also reduced, but because 
caplacizumab does not target the ongoing autoimmune 
response, the relapse rate shortly after withdrawal of 
the study drug per protocol (30 days after the last TPE 
session) was increased. Many relapsing patients had 
persistent severe ADAMTS13 deficiency, indicating 
that blocking the vWF A1 domain prevented platelet 
clumping in the microvasculature. Bleeding-related 
adverse events were more common in the caplacizumab 
arm (53% versus 38% in the placebo group), but most 
were mild and did not require an intervention, and the 
frequency of serious bleeding events was similar in both 
treatment arms195. Caplacizumab is currently under 
 further evaluation in the HERCULES trial, a  multicentre 
phase III study196.
Recombinant ADAMTS13. Recombinant ADAMTS13 
is expected to benefit patients with cTTP who depend 
on plasma therapy. Inaugural in vitro experiments on 
plasma from patients with cTTP as well as iTTP197,198 
have demonstrated that the addition of recombinant 
ADAMTS13 effectively restored vWF-cleaving activity. 
In the presence of functional ADAMTS13 inhibitory 
autoantibodies, the required amount of recombinant 
ADAMTS13 was dependent on the inhibitor titre198. 
Efficacy and feasibility were also proved in various 
animal models of cTTP and iTTP199–201. A phase I trial 
using recombinant ADAMTS13 (BAX930) in patients 
with cTTP has been completed202, and first results are 
expected in late 2017.
‘Second trigger’ hypothesis
Some patients with cTTP do not develop acute TTP for 
many years, and, similarly, some patients with iTTP 
may remain in remission while having undetectable 
levels of ADAMTS13 activity for prolonged periods of 
time19,23,188. These findings led to the hypothesis that a 
second hit or a trigger is needed to induce overt TTP203. 
Patients often report infections in the week or weeks 
preceding an acute TTP episode. In vitro, increased 
 levels of cytokines (for example, tumour necrosis factor 
and IL-8) that are released during infection and inflam-
mation stimulate human endothelial cells to release 
vWF from Weibel–Palade bodies204, whereas human 
neutrophil peptides, which are released from activated 
and degranulated neutrophils, inhibit proteolytic cleav-
age of vWF by ADAMTS13 in vitro205. Another pos-
sible trigger are nucleosomes, which are detected at 
presentation in the majority of patients with an acute 
TTP episode206. These nucleosomes are derived, at least 
in part, from neutrophil extracellular traps, which are 
networks made of nuclear DNA, histones, granular 
and cytoplasmic proteins that are released by neutro-
phils in response to infections. Neutrophil extracellular 
traps, circulating extracellular DNA and histones have 
been shown to be prothrombotic and may promote 
organ damage206.
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Disease modifiers
Given the overlapping clinical features between TTP 
and HUS, pre-eclampsia, HELLP syndrome and (cata-
strophic) antiphospholipid syndrome, the genes and 
proteins involved in these conditions might have a role 
as disease modifiers and modulators of the severity 
of TTP.
Other proteases as a possible rescue system. Other 
proteases might help to regulate the size of vWF multi-
mers, as vWF proteolysis has been observed in the acute 
phase of TTP when ADAMTS13 activity is undetect-
able207. In vitro studies have shown that various enzymes, 
including various leukocyte proteases142, plasmin208, 
granzyme B209 and thrombin210, can cleave vWF, and 
injection of streptokinase (to generate plasmin) attenu-
ated TTP symptoms in an Adamts13−/− mouse model of 
TTP211. Although it is tempting to assign a back-up role 
to some of these enzymes in the absence of ADAMTS13, 
this hypothesis has not been proved. Furthermore, 
plasmin, thrombin and factor Xa (although all in 
supra-physiological concentrations) have been reported 
to cleave ADAMTS13, thereby reducing its activity212. 
Interestingly, a case of acquired TTP has been described 
in which ADAMTS13 activity was severely deficient as 
ADAMTS13 was proteolysed during the acute phase of 
the disease, which was linked to an acquired, transient 
deficiency of α2-antiplasmin activity213.
β2-glycoprotein I. β2-glycoprotein I interacts with the 
vWF A1 domain in its glycoprotein Ib-binding conforma-
tion, that is, platelet-binding conformation, and thereby 
abrogates platelet binding to vWF. Anti-β2-glycoprotein I 
antibodies are found in patients with antiphospholipid 
syndrome and are thought to contribute to the pro-
thrombotic state in this condition. Du et al.214 found 
reduced levels of β2-glycoprotein I in patients with 
iTTP who present with acute TTP episodes and in 
remission, which directly correlated with ADAMTS13 
activity. In addition, this study showed that adhesion 
of β2-glycoprotein I to erythrocytes and platelets was 
enhanced in the presence of ultra-large vWF multimers 
or a hyperactive vWF A1 domain, which, at least in part, 
explains the reduced levels of  β2-glycoprotein I during 
acute iTTP episodes.
Alternative complement pathway. Secreted and 
endothelial cell-anchored ultra-large vWF multimers 
are hyperadhesive sites that initiate platelet adhesion 
and aggregation, but can also activate the alternative 
complement pathway215. In vitro, C3b, the active form 
of C3, binds to the endothelial cell-anchored ultra-large 
vWF multimers and initiates the assembly of C3 conver-
tase (C3b–Bb) and C5 convertase (C3b–Bb–C3b) on the 
multimer strings215 (FIG. 3b). In vivo, the activation of 
the alternative complement pathway by ultra-large vWF 
strings may progress further to generate terminal com-
plement complexes (C5b–9)216–218, possibly causing direct 
endothelial cell injury and stimulating endothelial cells 
to secrete additional ultra-large vWF multimeric strings.
The alternative complement pathway and its regu-
lators (CFH, CFI, MCP and thrombomodulin) are of 
particular interest because of their role in aHUS116, and 
because CFH has been reported to have vWF reduc-
tase capacity219,220. Noris et al.221 described three siblings 
affected by cTTP: two sisters with phenotypically distinct 
clinical courses (only one had renal involvement) and an 
asymptomatic brother. In addition to ADAMTS13 muta-
tions, the sister with renal involvement also carried a CFH 
mutation, previously described in aHUS, whereas the 
other two siblings did not carry it. Fan et al.222 reported 
that, in 32 patients with cTTP, of whom 13 had renal 
involvement including end-stage renal disease, missense 
sequence variants in genes encoding complement factors 
and complement regulatory proteins, previously reported 
to be associated with an increased risk for aHUS, had 
the same prevalence in patients, regardless of whether 
they had renal insufficiency or not. However, 1 out of 13 
patients with renal involvement carried a novel C3 muta-
tion, p.K155Q, located in the C3 macroglobulin-like 2 
domain, a region where aHUS-associated mutations 
cluster. Although complement aberrations might con-
tribute to renal complications, there have to be other, 
still  unrecognized factors shaping the phenotype in cTTP.
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